Dr. Andrew Rut, CEO of MyMeds&Me, will be on the panel for the biannual pvlegal meeting in New Jersey, USA 19 July 2018. Hosted by Celgene the pvlegal biannual meeting will bring together pharmaceutical, healthcare and compliance professionals to discuss issues relating to drug and device safety in the life sciences sector. It is an interactive meeting which will include presentations on global regulatory and litigation developments, benchmarking trends, and practical case studies on industry issues.
Andrew will be part of the panel discussing key themes in the global pharmacovigilance industry. Topics will include signal detection trends in product liability litigation, approaches to safety data exchange agreements, data privacy and the role of artificial intelligence in pharmacovigilance.
Dr. Andrew Rut, CEO of MyMeds&Me said: “I am delighted to be a panelist at pvlegal’s biannual meeting, which will provide a great opportunity to discuss the major issues in pharmacovigilance and share best practice with colleagues from across the US and the EU.
“A key topic for discussion will be AI, which is being explored to process adverse events on marketed products. Adverse drug events are becoming a greater issue for healthcare systems; correlated with poor health outcomes and an avoidable misuse of resources. But despite the clear advantages of utilising AI in healthcare, there are certain challenges for drug safety including transparency of the algorithms used. We must be mindful that insights delivered by AI will only be as good as the fundamental data it analyses; no amount of polishing by AI tools will rectify critical gaps in information that can only be addressed at source. There needs to be greater scrutiny around the processing of data to promote the collection of relevant data first time right at source.”
Dr. Andrew Rut is in frequent attendance at conferences around patient safety and regulation; he spoke most recently at FutureLink 2018 in Munich, Germany 5-7 June on transforming adverse event reporting and patient safety with serialised medicine.
